×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AZN – astrazeneca plc - american depositary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AZN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
04:16 am
azn
China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics [Yahoo! Finance]
Low
Report
China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics [Yahoo! Finance]
12/4
06:27 pm
azn
Has AstraZeneca's Strong 30% Rally Left Further Upside in 2025? [Yahoo! Finance]
Low
Report
Has AstraZeneca's Strong 30% Rally Left Further Upside in 2025? [Yahoo! Finance]
12/4
02:59 pm
azn
Massive U.S. drug spending gives Trump trade leverage [Globe and Mail, The (Toronto, Canada)]
Low
Report
Massive U.S. drug spending gives Trump trade leverage [Globe and Mail, The (Toronto, Canada)]
12/4
07:00 am
azn
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
Low
Report
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
12/3
07:02 pm
azn
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
12/3
08:44 am
azn
AstraZeneca (NASDAQ:AZN) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
AstraZeneca (NASDAQ:AZN) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/3
07:19 am
azn
AstraZeneca (NASDAQ:AZN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
AstraZeneca (NASDAQ:AZN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/2
09:18 am
azn
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Low
Report
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
01:48 pm
azn
Form 6-K ASTRAZENECA PLC For: Dec 04
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 04
12/1
11:47 am
azn
Form 6-K ASTRAZENECA PLC For: Dec 01
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 01
12/1
11:41 am
azn
Form 6-K ASTRAZENECA PLC For: Dec 01
Low
Report
Form 6-K ASTRAZENECA PLC For: Dec 01
11/26
06:27 am
azn
Form 6-K ASTRAZENECA PLC For: Nov 26
Low
Report
Form 6-K ASTRAZENECA PLC For: Nov 26
11/24
11:22 am
azn
Form 6-K ASTRAZENECA PLC For: Nov 24
Low
Report
Form 6-K ASTRAZENECA PLC For: Nov 24
11/20
08:32 am
azn
Form 6-K ASTRAZENECA PLC For: Nov 20
Low
Report
Form 6-K ASTRAZENECA PLC For: Nov 20
11/17
12:53 pm
azn
Form 6-K ASTRAZENECA PLC For: Nov 17
Low
Report
Form 6-K ASTRAZENECA PLC For: Nov 17
11/14
04:13 pm
azn
Form 25-NSE ASTRAZENECA PLC Filed by: Nasdaq Stock Market LLC
Low
Report
Form 25-NSE ASTRAZENECA PLC Filed by: Nasdaq Stock Market LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
AstraZeneca's combo lung cancer treatment fails late-stage study main goal [Reuters (UK)]
8.3%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
4/9 Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca [Yahoo! Finance News] 7.6%
3/3 Form 20-F ASTRAZENECA PLC For: Dec 31 6.8%
3/26 Form 6-K ASTRAZENECA PLC For: Mar 26 5.9%
10/24 AstraZeneca tops sales forecasts on China, new drug boosts [Reuters] 5.7%
7/25 AstraZeneca quarterly product sales beat on cancer drug strength [Reuters (UK)] 5.7%
3/30 Form 6-K ASTRAZENECA PLC For: Mar 30 5.5%
2/29 AstraZeneca plc (NYSE: AZN) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock. 4.5%
3/19 Form 6-K ASTRAZENECA PLC For: Mar 19 3.7%
4/14 AstraZeneca to test impact of cancer drug Calquence on coronavirus patients [Reuters] 2.9%
TOP News Decliners
3/7
Amarin Stock Looks Like a Heart-Healthy Buy on the Dip [Yahoo! Finance News]
-4.1%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
2/27 Form 6-K ASTRAZENECA PLC For: Feb 27 -3.9%
3/20 Form 6-K ASTRAZENECA PLC For: Mar 20 -3.5%
3/12 Form 6-K ASTRAZENECA PLC For: Mar 12 -2.9%
10/1 UPDATE 1-AstraZeneca's combo lung disease therapy fails to win FDA approval [Yahoo! Finance News] -2.7%
3/6 AstraZeneca's combo cancer treatment fails to meet late-stage study main goal [Reuters] -2.4%
12/30 AstraZeneca-Merck's Lynparza gets FDA okay to treat pancreatic cancer [Reuters] -2.3%
9/28 LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer -2.2%
10/1 AstraZeneca sells acid reflux drug rights to Germany's Cheplapharm [Reuters] -2.0%
8/14 LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: